Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer

C. Dittrich, B. Coudert, L. Paz-Ares, F. Caponigro, M. Salzberg, T. Gamucci, X. Paoletti, C. Hermans, D. Lacombe, P. Fumoleau

Research output: Contribution to journalArticle

Abstract

XR5000 is a tricyclic carboxamide-based cytotoxic agent that binds to DNA by intercalation and stimulates DNA cleavage by inhibition of both topoisomerase I and II. The aim of this study was to evaluate the antitumoral activity and safety profile of XR5000 given as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Patients received XR5000 at the dose of 3010 mg/m2 as a 120-h central venous infusion every 3 weeks. The 15 patients (median age 56 years, range 48-71 years) enrolled had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (3 patients), 1 (11 patients) or 2 (1 patient). A total of 32 cycles of XR5000 (median 2, range 1-6) were given to 14 patients. No objective response (assessed according to World Health Organization (WHO) criteria) was documented in the 12 evaluable patients by an external review panel; in 4 out of the 12 patients disease stabilisation was recorded. The following toxicities graded according to the Common Toxicity Criteria (CTC) version 2.0. were observed: one grade 3 and two grade 4 granulocytopenia, one grade 3 and one grade 4 thrombocytopenia, one grade 3 deep venous thrombosis, one grade 3 fatigue, and grade 3 undocumented epileptic seizures which led to death in 2 patients. With only 4 out of 12 patients reaching stable disease when using this dose and regimen, further evaluation of XR5000 in advanced NSCLC is not justified.

Original languageEnglish
Pages (from-to)330-334
Number of pages5
JournalEuropean Journal of Cancer
Volume39
Issue number3
DOIs
Publication statusPublished - Feb 2003

    Fingerprint

Keywords

  • Advanced non-small cell lung cancer (NSCLC)
  • Phase II study
  • Topoisomerase I and II inhibitor
  • XR5000

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this